Clinical trials: Heparin-Induced Thrombocytopenia
Thrombocytopenia, Thrombosis
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT)…
- Trial name
- NCT00039858
- Testing
- Argatroban
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Encysive Pharmaceuticals
Heparin-Induced Thrombocytopenia, Thrombosis
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
Primary Objective: To assess the safety of bivalirudin as an alternative anticoagulant therapy for patients with new or previous heparin-induced thrombocytopenia (HIT) / heparin-induced thrombocytopenia and thrombosis syndrome…
- Trial name
- NCT00043940
- Testing
- bivalirudin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Medicines Company
Heparin-induced Thrombocytopenia
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)
- Trial name
- HITSOVA (NCT03809481)
- Testing
- Danaparoid Sodium, Argatroban
- Where
- 35 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 7 people
- Sponsor
- Aspen Global Incorporated
Heparin-induced Thrombocytopenia
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of…
- Trial name
- NCT05325346
- Testing
- VLX-1005, Argatroban
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Veralox Therapeutics
Thrombosis
Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis
The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.
- Trial name
- DESIR-ABLE (NCT00913133)
- Testing
- Desirudin
- Where
- 16 sites in United States
- Volunteers
- 516 people
- Sponsor
- Canyon Pharmaceuticals, Inc.
Cardiovascular Disease, Coronary Artery Bypass Surgery
Angiomax in Patients With HIT/HITTS Type II Undergoing CPB
The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary…
- Trial name
- HIT/TS (NCT00079508)
- Testing
- Angiomax (bivalirudin)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- The Medicines Company
Heparin-induced Thrombocytopenia Type II
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral…
- Trial name
- NCT00861692
- Testing
- argatroban
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Tanabe Pharma Corporation
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT).
- Trial name
- NCT05785819
- Testing
- VLX-1005
- Where
- 14 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veralox Therapeutics
Suspected Heparin-Induced Thrombocytopenia
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
Compare Clinical Success and Costs in two Arms
- Trial name
- HIT (NCT00787332)
- Testing
- Desirudin or Argatroban®
- Where
- 24 sites in United States
- Volunteers
- 16 people
- Sponsor
- Canyon Pharmaceuticals, Inc.
Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome
Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients
To monitor the frequency of the development of thrombocytopenia in patients with Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome receiving bivalirudin during Percutaneous Coronary…
- Trial name
- NCT00759083
- Testing
- bivalirudin
- Where
- United States
- Sponsor
- The Medicines Company
Thrombocytopenia, Thrombosis
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS)…
- Conditions
- Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
- Trial name
- NCT00073580
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- The Medicines Company
Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II
The purpose of this retrospective registry is to collect data about patients with acute HIT II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid, Argatroban or Fondaparinux.
- Trial name
- NCT01304238
- Testing
- lepirudin, danaparoid, argatroban
- Volunteers
- 195 people
- Sponsor
- GlaxoSmithKline